PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA • Opioids - Novel Abuse deterrent Formulation Technologies & Pipeline drugs • Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of Pain
PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA • Opioids - Novel Abuse deterrent Formulation Technologies & Pipeline drugs • Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of Pain

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or Email: pdb@bioportholio.co.uk
PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA • Opioids - Novel Abuse deterrent Formulation Technologies & Pipeline drugs • Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of Pain

Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chronic Pain (2016) are definite steps taken by FDA in last two years for creating “Abuse Deterrent Era” in a short span to stop opioid abuse and reversing opioid epidemic in USA. There were around 18,893 deaths involving prescription of opioids in the United States in 2014 which was up 16% from 2013 as per NCHS (National Center for Health Statistics).

Around +6 plus extended release abuse deterrent formulations with Abuse deterrent (AD) labels are approved in last two years (Xtampza ER, MorphaBond ER, Hysingla ER, Embeda ER, Targiniq ER, Oxydo) and are expected to provide improvements over existing formulations for abuse deterrent purpose. But they have some limitation for restricting abuse mainly through oral intake- swallowing a number of intact tablets or capsules. Despite, Extended release (ER) Abuse Deterrent Formulations partly control Opioids abuse (through nasal or injection routes), ER opioids has high potential of abuse, its AD formulation add significant value to create “Abuse Deterrent Era” in the coming time.

Around 20 plus Abuse Deterrent Formulations of opioids are in the pipeline and most of them are ER formulations which use different AD tech platform to make its ADF. Amongst these pipeline ADF drugs, 6 are of Hydrocodone, 8 are of Morphine and 6 are of Oxycodone based ADF formulations.

New NCEs targeting Opioids receptor are in pipeline which reduces Opioids abuse by its MoA (slow rate of entry in Brain) and may have potential to deal with reducing opioid abuse through restricting oral intake in coming years.

US Opioids market is of $8b in size and of which extended release formulations contribute 50%. ADF ER formulations and its generic versions & New NCEs targeting Opioid receptor will drive the growth of opioid market in US and Europe in coming years.

In this report, we have discussed a number of novel delivery technologies employed in the formulating abuse deterrent product, technologies employed in enhancing patient compliances, emerging novel mechanisms and late stage pipeline drugs in the management of pain.

Late stage NCE pipeline drugs (Cebranopadol, Mirogabalin, NKT-181, AVP-923,…) and Novel technologies targeting formulation change in old generic drugs (ORB-201, OX-51, ARX-04,CL-108, once daily Pregabalin..) for pain management has potential to reduce opioids use in future to treat pain. While TRKA receptor antagonist, NAV1.7 sodium channel modulator inhibitor and angiotension II antagonist are few new MoA which has promising drug in clinical development for moderate to severe pain management.

Additional Details

Publisher : MP Advisors
Reference : 4493
Number of Pages : 135
Report Format : PDF
Publisher Information : https://www.bioportfolio.co.uk/product/20130
info@bioportfolio.co.uk to order
Table Of Contents for PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA • Opioids - Novel Abuse deterrent Formulation Technologies & Pipeline drugs • Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of Pain [Published by MP Advisors]

• Executive Summary
Pros & Cons analysis based on reported PhII data. CL-108d. Hydromorphonee. Convergence/ biogen Idec-CNV-219794f. Convergence/ biogen Idec-CNV-1014802g. Sativexh. Once daily pregabalin. Topical clonidine gelj. Topical ketamine and amitrallnek. Amorsa therapeuticsl. Pregabalin CRM. Eladurn. GRC-17536o. DWP05195p. AVP-123q. Algiax Pharmaceuticals Appendix - I FDA Guidelines for the development of abuse Deterrent Formulations. Types of Abuse deterrent formulation as per current guidance. Pre market studies. Post market studies. Labeling Recommendations Appendix- II General Principles for Evaluating the Abuse deterrent Generic Solid Oral Opioid Drug Products? Need for regulatory filing and other key requirements? Route of Abuse deterrent? Comparative in Vitro Studies? Other Consideration? Data Analysis? Additional companies mentioned: AbbVie• AcelRx pharma• Acorda Therapeutics• Actavis• Acura Pharma• Acorda Therapeutics• Altus formulations• Alkermes• Algiax Pharmaceuticals• Amorsa Therapeutics• AnGes• AstraZeneca• Balerna• Biogen• BioDelivery Sciences International Inc• Biopharma• Cara Therapeutics• Catalent• Charleston• Celltech• Collegium Pharma• Convergence• Columbia Labs• Convatech• Daiichi Sankyo• Daewoong• Depomed• Durect• Egalet• Eli Lilly• Elite Pharma• Endo• Ensyce Bioscience• EpiCep• Flamel Technologies• Flexion Therapeutics• Forest• Glenmark• Grunenthal• GlaxoSmithKline• GW Pharma• Immune Pharmaceuticals• Impax Pharmaceuticals• Inspirion• Intelli Pharmaceuticals• IRX Therapeutics• Johnson and Johnson• KemPharm• Kineta• Kunwha Pharmaceutical• Medallion Therapeutics• Mallinckrodt• Nektar• Novartis• Noven• Orbis Biosciences• Orexo• Otsuka• Pain Therapeutics• Pfizer• ProPharma• Purdue• Recro Pharma• Relmada Therapeutics• Reckitt Benckiser pharmaceutical• Signature Therapeutics• Spinifex pharma• SPR Therapeutics• Strativa• Teikoku• Teva• Tesa Labtec GmpH• Trevena Inc• Tris Pharma• Valeant• ViroMed• Wooddiff Lake• Xenon Pharma• XenoPort
How to Buy...

PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA • Opioids - Novel Abuse deterrent Formulation Technologies & Pipeline drugs • Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of Pain [Published by MP Advisors]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/20130

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: ____________________________________________
Job Title: ______________________________________________
Your Email: ____________________________________________
Your Contact Phone: ____________________________________
Company Name: _________________________________________
Address: ______________________________________________
Post/Zip Code: __________________________________________
Country: ________________________________________________
P.O. Number: __________________________________________
Any Other Instructions: __________________________________

Price: ○ &##@#36;;7000 | Price

Payment Options: (please tick one)
○ Online Credit Card (we will email you the invoice with a payment link)
○ Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: __________________________________

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.